Non-Invasive Monitoring Systems (NIMU) 10-Q 13 Dec 19 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Oct. 31, 2019	Dec. 13, 2019
Cover [Abstract]
Entity Registrant Name	NON INVASIVE MONITORING SYSTEMS INC /FL/
Entity Central Index Key	0000720762
Document Type	10-Q
Document Period End Date	Oct. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		154,810,655
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Oct. 31, 2019	Jul. 31, 2019
Current assets
Cash	$ 333	$ 353
Prepaid expenses, deposits, and other current assets	4	5
Current assets - discontinued operations		3
Total current assets	337	361
Total assets	337	361
Current liabilities
Accounts payable and accrued expenses	256	225
Current liabilities - discontinued operations	55	55
Total current liabilities	311	280
Total liabilities	311	280
Commitments and contingencies (Note 9)
Shareholders' equity (deficit)
Series B Preferred Stock, par value $1.00 per share; 100 shares authorized, issued and outstanding; liquidation preference $10
Common Stock, par value $0.01 per share; 400,000,000 shares authorized; 154,810,655 shares issued and outstanding	1,548	1,548
Additional paid in capital	26,574	26,574
Accumulated deficit	(28,096)	(28,041)
Total shareholders' equity	26	81
Total liabilities and shareholders' equity	$ 337	$ 361

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Oct. 31, 2019	Jul. 31, 2019
Statement of Financial Position [Abstract]
Series B Preferred stock, par value	$ 1	$ 1
Series B Preferred stock, shares authorized	100	100
Series B Preferred stock, shares issued	100	100
Series B Preferred stock, shares outstanding	100	100
Series B Preferred stock, liquidation preference	$ 10	$ 10
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	154,810,655	154,810,655
Common stock, shares outstanding	154,810,655	154,810,655

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Operating costs and expenses
General and administrative	$ 52	$ 135
Total operating costs and expenses	52	135
Operating loss	(52)	(135)
Interest expense, net		(59)
Loss from continuing operations	(52)	(194)
Loss from discontinued operations	(3)	(13)
Net loss	$ (55)	$ (207)
Weighted average number of common shares outstanding - Basic and diluted	154,811	79,007
Basic and diluted net loss per common share from continuing operations	$ 0	$ 0
Basic and diluted net income (loss) per common share from discontinued operations	0	0
Basic and diluted loss per common share	$ 0	$ 0

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in-Capital [Member]	Accumulated Deficit [Member]	Total
Balance, beginning at Jul. 31, 2018		$ 62	$ 3	$ 790	$ 21,930	$ (26,463)	$ (3,678)
Balance, beginning shares at Jul. 31, 2018	100	62,048	2,782	79,007,423
Net loss						(207)	(207)
Balance, ending at Oct. 31, 2018		$ 62	$ 3	$ 790	21,930	(26,670)	(3,885)
Balance, ending shares at Oct. 31, 2018	100	62,048	2,782	79,007,423
Balance, beginning at Jul. 31, 2019				$ 1,548	26,574	(28,041)	81
Balance, beginning shares at Jul. 31, 2019	100			154,810,655
Net loss						(55)	(55)
Balance, ending at Oct. 31, 2019				$ 1,548	$ 26,574	$ (28,096)	$ 26
Balance, ending shares at Oct. 31, 2019	100			154,810,655

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Operating activities
Net Loss	$ (55)	$ (207)
Add back: loss attributable to discontinued operations	3	13
Changes in operating assets and liabilities
Prepaid expenses, deposits and other current assets	1	(6)
Accounts payable and accrued expenses	31	162
Net cash used in continuing operations	(20)	(38)
Net cash used in discontinued operations		(13)
Net cash used in operating activities	(20)	(51)
Net decrease in cash from continuing operations	(20)	(51)
Cash, beginning of period	353	90
Cash, end of period	$ 333	$ 39

Organization and Business

Organization and Business	3 Months Ended
	Oct. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	1. ORGANIZATION AND BUSINESS Organization. ® Business. Discontinued Operations. Accordingly, the Company determined that the assets and liabilities met the discontinued operations criteria in Accounting Standards Codification 205-20-45 and were classified as discontinued operations at October 31, 2019 and July 31, 2019 and for the three months ended October 31, 2019 and 2018. Going Concern. The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. As reflected in the accompanying consolidated financial statements, the Company had net losses from continuing operations of approximately $52,000and $194,000 for the three months ended October 31, 2019 and 2018, respectively, and has experienced continuous cash outflows from operating activities. The Company also has an accumulated deficit of approximately $28.1 million as of October 31, 2019. The Company had $333,000 of cash at October 31, 2019 and working capital of approximately $26,000. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The Company is seeking potential mergers, acquisitions and strategic collaborations. There is no assurance that the Company will be successful in this regard, and, if not successful, that it will be able to continue its business activities. The accompanying consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. Equity Exchange Agreement. On August 4, 2019, IRAFG delivered to the Company notice of termination of the Exchange Agreement pursuant to Section 8.01(b)(i) of that agreement due to the failure of the Exchange to have closed on or prior to the Outside Date. No termination fees, penalties or other amounts are payable by the Company in respect of such termination.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Oct. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation. Discontinued Operations. Discontinued operations expense allocations, consisting of warehouse rent and other inventory related expenses incurred by us, are directly attributed to discontinued operations (see Note 3). Use of Estimates. Cash and Cash Equivalents. Income Taxes. The Company files its tax returns as prescribed by the laws of the jurisdictions in which it operates. Tax years ranging from 2015 to 2019 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. It is the Company’s policy to include income tax interest and penalty expense in its tax provision. Stock-based compensation. Fair Value of Financial Instruments. Loss Contingencies. Recent Accounting Pronouncements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230) In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases Leases

Discontinued Operations

Discontinued Operations	3 Months Ended
	Oct. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	3. DISCONTINUED OPERATIONS On May 3, 2019 the Company exchanged its inventory for forgiveness of accrued unpaid rent. Concurrent with the exchange management with the appropriate level of authority determined to discontinue the operations of the product segment. The detail of the consolidated balance sheets, the consolidated statement of operations and consolidated cash flows for the discontinued operations is as stated below: As of October 31, 2019 As of July 31, 2019 Current assets – discontinued operations Prepaid expenses $ - $ 3 Total current assets – discontinued operations - 3 Total assets – discontinued operations $ - $ 3 Current liabilities – discontinued operations Accounts payable and accrued expenses $ 55 $ 55 Total current liabilities – discontinued operations 55 55 Total liabilities – discontinued operations $ 55 $ 55 For the three months ended October 31, 2019 For the three months ended October 31, 2018 Selling, general and administrative expenses $ (3 ) $ (13 ) Loss from discontinued operations $ (3 ) $ (13 ) Basic and diluted loss per common share $ (0.00 ) $ (0.00 ) For the three months ended October 31, 2019 For the three months ended October 31, 2018 Cash used in operations for discontinued operations: Loss from discontinued operations $ (3 ) $ (13 ) Prepaid expenses 3 - Cash used in discontinued operations $ - $ (13 )

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Oct. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	4. STOCK-BASED COMPENSATION The Company measures the cost of employee, officer and director services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. The Company did not record stock-based compensation for the three months ended October 31, 2019 and 2018. In November 2010, the Company’s Board and Compensation Committee approved the Non-Invasive Monitoring Systems, Inc. 2011 Stock Incentive Plan (the “2011 Plan”). Awards granted under the 2011 Plan may consist of incentive stock options, stock appreciation rights (SAR), restricted stock grants, restricted stock units (RSU) performance shares, performance units or cash awards. Subject to adjustment in certain circumstances, the 2011 Plan `authorizes up to 4,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2011 Plan. The 2011 Plan was approved by our shareholders in March 2012 and no awards have been granted under the 2011 Plan as of October 31, 2019. As of October 31, 2019, there were no outstanding stock options and there were no unrecognized costs related to outstanding stock options. The Company did not grant any stock options during the three months ended October 31, 2019 or 2018.

Notes Payable

Notes Payable	3 Months Ended
	Oct. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	5. NOTES PAYABLE The Company entered into various notes payable with related parties from 2010 to 2018 with an aggregate principal total of $2,175,000 and with an unrelated third party for $50,000 for total principal amount of $2,225,000. The interest rate was 11% and the maturity date was July 31, 2020. The Company could prepay these notes in advance of the maturity date without premium or penalty. On December 21, 2018, the Company issued 50,584,413 shares of Common Stock in exchange for the extinguishment of debt and related accrued interest totaling approximately $3,541,000. The Company incurred interest expense related to the Credit Facility and notes payable of $59,000 for the three months ended October 31, 2018 and $0 for the three months ended October 31, 2019. The Company maintains a Note and Security Agreement with Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock (“Frost Gamma”), and Hsu Gamma Investments, LP, an entity controlled by the Company’s Chairman and Interim CEO (“Hsu Gamma” and together with Frost Gamma, the “Lenders”), pursuant to which the Lenders have provided a revolving credit line (the “Credit Facility”) in the aggregate principal amount of up to $1.0 million, secured by all of the Company’s personal property. The interest rate payable on amounts outstanding under the Credit Facility is 11% per annum and increases to 16% per annum after the Credit Facility Maturity Date or after an event of default. The Company is permitted to borrow and reborrow from time to time under the Credit Facility until July 31, 2020 (the “Credit Facility Maturity Date”). The balance of the principal due under the Credit Facility was $0 at July 31, 2019 and October 31, 2019.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Oct. 31, 2019
Equity [Abstract]
Shareholders' Equity	6. SHAREHOLDERS’ EQUITY The Company has three classes of Preferred Stock. Holders of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock are entitled to vote with the holders of common stock as a single class on all matters. Series B Preferred Stock is not redeemable by the Company and has a liquidation value of $100 per share, plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $10 per share, if declared. Series C Preferred Stock is redeemable by the Company at a price of $0.10 per share upon 30 days prior written notice. This series has a liquidation value of $1.00 per share plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $0.10 per share, if declared. Each share of Series C Preferred Stock is convertible into 25 shares of the Company’s common stock upon payment of a conversion premium of $4.20 per share of common stock. The conversion rate and the conversion premium are subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. In February 2019, all outstanding shares of Series C Preferred Stock were redeemed by the Company following 30 days written notice. The redemption amount for the 62,048 Series C Preferred Stock was approximately $25,000 at a rate of $0.40 per share of which approximately $15,000 was paid and approximately $10,000 is included in accrued expenses at October 31, 2019. The redeemed Series C Preferred Stock were then cancelled following the redemption. Series D Preferred Stock is not redeemable by the Company. This series has a liquidation value of $1,500 per share, plus declared and unpaid dividends, if any. Each share of Series D Preferred Stock is convertible into 5,000 shares of the Company’s common stock. The conversion rate is subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. In February 2019, all holders of the 2,782 outstanding shares of Series D Preferred Stock converted their shares to common stock. As a result, the Company issued 13,910,000 common shares. No preferred stock dividends were declared for the three months ended October 31, 2019 and 2018. The Company did not issue any shares of the Company’s common stock during the three months ended October 31, 2019 and 2018.

Basic and Diluted Loss Per Shar

Basic and Diluted Loss Per Share	3 Months Ended
	Oct. 31, 2019
Earnings Per Share [Abstract]
Basic and Diluted Loss Per Share	7. BASIC AND DILUTED LOSS PER SHARE Basic net loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the three months ended October 31, 2019 and 2018, no dilution adjustment has been made to the weighted average outstanding common shares because the assumed exercise of outstanding options and warrants and the conversion of preferred stock would be anti-dilutive. There are no options or warrants outstanding as of October 31, 2019 and 2018. Potential common shares not included in calculating diluted net loss per share are as follows: October 31, 2019 October 31, 2018 Series C Preferred Stock - 1,551,200 Series D Preferred Stock - 13,910,000 Total - 15,461,200

Related Party Transactions

Related Party Transactions	3 Months Ended
	Oct. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	8. RELATED PARTY TRANSACTIONS Dr. Hsiao, Dr. Frost and directors Steven Rubin and Rao Uppaluri are each stockholders, current or former officers and/or directors or former directors of TransEnterix, Inc. (formerly SafeStitch Medical, Inc.) (“TransEnterix”), a publicly-traded medical device company. The Company’s Chief Financial Officer also served as the Chief Financial Officer of TransEnterix until October 2, 2013. The Company’s Chief Financial Officer continued as an employee of TransEnterix until March 3, 2014, during which he supervised the Miami based accounting staff of TransEnterix under a cost sharing arrangement whereby the total salaries of the Miami based accounting staff was shared by the Company and TransEnterix. The Chief Financial Officer continues to serve as the Chief Financial Officer of Cocrytal Pharma, Inc., a clinical stage biotechnology company, and in which Steve Rubin and Jane Hsiao, serve on the Board. Since December 2009, the Company’s Chief Legal Officer has served under a similar cost sharing arrangement as the Chief Legal Officer of TransEnterix. The Company signed a five year lease for office space in Miami, Florida with a company controlled by Dr. Phillip Frost, who is the beneficial owner of more than 10% of the Company’s common stock. The rental payments under the Miami office lease, which commenced January 1, 2008 and expired on December 31, 2012, were approximately $1,250 per month and then continued on a month-to-month basis. In February 2016 the rent was reduced to $0 per month. For the three months ended October 31, 2019 and 2018, the Company did not record any rent expense related to the Miami lease. At October 31, 2019 and 2018, approximately $0 and $76,000 in rent was payable, respectively. The Company is under common control with multiple entities and the existence of that control could result in operating results or financial position of each individual entity significantly different from those that would have been obtained if the entities were autonomous. One of those related parties, OPKO Health, Inc. (“OPKO”) and the Company are under common control and OPKO has a one percent ownership interest in the Company that OPKO has accounted for as an equity method investment due to the ability to significantly influence the Company.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Oct. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Leases. The Company was under an operating lease agreement for our corporate office space that expired in 2012. The lease currently continues on a month to month basis at no cost. We housed our inventory in approximately 4,000 square feet of warehouse space in Pembroke Park, Florida. The lease commenced September 15, 2014 and originally expired on September 30, 2015 and we exercised our option to renew the lease and extended the expiration to September 15, 2017. Following the expiration, we have remained on a month-to-month term. On May 3, 2019 the Company exchanged inventory for forgiveness of $15,000 of accrued unpaid rent. The Company had previously written off the value of this inventory resulting in a gain on the forgiveness of approximately $15,000. The Company no longer leases this Pembroke Park warehouse following the sale of inventory. Product Development and Supply Agreement. In September 2007, the Company entered into a Product Development and Supply Agreement (the “Agreement”) with Sing Lin Technologies Co. Ltd., a company based in Taichung, Taiwan (“Sing Lin”). Pursuant to the Agreement, the Company consigned to Sing Lin the development and design of the next generation Exer-Rest and related devices. The Agreement commenced as of September 3, 2007 and had a term that extended three years from the acceptance by NIMS of the first run of production units. Thereafter, the Agreement automatically renewed for successive one year terms unless either party sent the other a notice of non-renewal. Either party was permitted to terminate the Agreement with ninety days prior written notice. Upon termination, each party’s obligations under the Agreement were to be limited to obligations related to confirmed orders placed prior to the termination date. Pursuant to the Agreement, Sing Lin designed, developed and manufactured the tooling required to manufacture the acceleration therapeutic platforms for a total cost to the Company of $471,000. Sing Lin utilized the tooling in the performance of its production obligations under the Agreement. The Company paid Sing Lin $150,000 of the tooling cost upon execution of the Agreement and $150,000 upon the Company’s approval of the product prototype concepts and designs. The balance of the final tooling cost became due and payable in September 2008 upon acceptance of the first units produced using the tooling, and was paid in full during the year ended July 31, 2009. Under the now-terminated Agreement, the Company also granted Sing Lin the exclusive distribution rights for the products in certain countries in the Far East, including Taiwan, China, Japan, South Korea, Malaysia, Indonesia and certain other countries. Sing Lin agreed not to sell the Products outside its geographic areas in the Far East. The Agreement provided for the Company to purchase approximately $2.6 million of Exer-Rest units within one year of the September 2008 acceptance of the final product. The Agreement further provided for the Company to purchase $4.1 million and $8.8 million of Exer-Rest products in the second and third years following such acceptance, respectively. These minimum purchase amounts were based upon 2007 product costs multiplied by volume commitments. Through October 31, 2019, the Company had paid Sing Lin $1.7 million in connection with orders placed through that date. As of October 31, 2019, the Company has approximately $41,000 of payables due to Sing Lin. As of October 31, 2019, aggregate minimum future purchases under the Agreement totaled approximately $13.9 million. As of October 31, 2019, the Company had not placed orders sufficient to meet the first-year or second-year minimum purchase obligations under the Agreement. The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement. As of December 13, 2019, Sing Lin has not followed up on its July 2010 demand. There can be no assurance that Sing Lin will not attempt to enforce its remedies under the Agreement, or pursue other potential remedies. The Company believes that Sing Lin in no longer in business.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Oct. 31, 2019
Accounting Policies [Abstract]
Consolidation	Consolidation.
Discontinued Operations	Discontinued Operations. Discontinued operations expense allocations, consisting of warehouse rent and other inventory related expenses incurred by us, are directly attributed to discontinued operations (see Note 3).
Use of Estimates	Use of Estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents.
Income Taxes	Income Taxes. The Company files its tax returns as prescribed by the laws of the jurisdictions in which it operates. Tax years ranging from 2015 to 2019 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. It is the Company’s policy to include income tax interest and penalty expense in its tax provision.
Stock-based Compensation	Stock-based compensation.
Fair Value of Financial Instruments	Fair Value of Financial Instruments.
Loss Contingencies	Loss Contingencies.
Recent Accounting Pronouncements	Recent Accounting Pronouncements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230) In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases Leases

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Oct. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Balance Sheets of Discontinued operations	The detail of the consolidated balance sheets, the consolidated statement of operations and consolidated cash flows for the discontinued operations is as stated below: As of October 31, 2019 As of July 31, 2019 Current assets – discontinued operations Prepaid expenses $ - $ 3 Total current assets – discontinued operations - 3 Total assets – discontinued operations $ - $ 3 Current liabilities – discontinued operations Accounts payable and accrued expenses $ 55 $ 55 Total current liabilities – discontinued operations 55 55 Total liabilities – discontinued operations $ 55 $ 55
Schedule of Statement of Operations for Discontinued Operations	For the three months ended October 31, 2019 For the three months ended October 31, 2018 Selling, general and administrative expenses $ (3 ) $ (13 ) Loss from discontinued operations $ (3 ) $ (13 ) Basic and diluted loss per common share $ (0.00 ) $ (0.00 )
Schedule of Cash Flows of Discontinued Operations	For the three months ended October 31, 2019 For the three months ended October 31, 2018 Cash used in operations for discontinued operations: Loss from discontinued operations $ (3 ) $ (13 ) Prepaid expenses 3 - Cash used in discontinued operations $ - $ (13 )

Basic and Diluted Loss Per Sh_2

Basic and Diluted Loss Per Share (Tables)	3 Months Ended
	Oct. 31, 2019
Earnings Per Share [Abstract]
Schedule of Common Shares Not Included in Calculation of Diluted Net Loss Per Share	Potential common shares not included in calculating diluted net loss per share are as follows: October 31, 2019 October 31, 2018 Series C Preferred Stock - 1,551,200 Series D Preferred Stock - 13,910,000 Total - 15,461,200

Organization and Business (Deta

Organization and Business (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net losses from continuing operation	$ (52)	$ (194)
Accumulated deficit	(28,096)		$ (28,041)
Cash	333		$ 353
Working capital	26
Inventory

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Cash	$ 333	$ 353
Minimum [Member]
Income tax examination year under examination	2015
Maximum [Member]
Income tax examination year under examination	2019

Discontinued Operations - Sched

Discontinued Operations - Schedule of Balance Sheets of Discontinued Operations (Details) - USD ($) $ in Thousands	Oct. 31, 2019	Jul. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Prepaid expenses		$ 3
Total current assets - discontinued operations		3
Total assets - discontinued operations		3
Accounts payable and accrued expenses	55	55
Total current liabilities - discontinued operations	55	55
Total liabilities - discontinued operations	$ 55	$ 55

Discontinued Operations - Sch_2

Discontinued Operations - Schedule of Statement of Operations for Discontinued Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Selling, general and administrative expenses	$ (3)	$ (13)
Loss from discontinued operations	$ (3)	$ (13)
Basic and diluted loss per common share	$ 0	$ 0

Discontinued Operations - Sch_3

Discontinued Operations - Schedule of Cash Flows of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Loss from discontinued operations	$ (3)	$ (13)
Prepaid expenses	3
Cash used in discontinued operations		$ (13)

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Nov. 30, 2010
Stock based compensation
Number of stock options granted
Stock options, outstanding
2011 Stock Incentive Plan [Member] | Maximum [Member]
Maximum number of shares authorized for issuance under the plan			4,000,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($) $ in Thousands	Dec. 21, 2018	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019
Short-term Debt [Line Items]
Debt conversion of common stock issued	50,584,413
Accrued interest related debt	$ 3,541
Interest expenses		$ 0	$ 59
Lenders [Member]
Short-term Debt [Line Items]
Line of credit		0		$ 0
Note and Security Agreement [Member] | Dr. Phillip Frost [Member]
Short-term Debt [Line Items]
Ownership percentage	10.00%
Note and Security Agreement [Member] | Lenders [Member]
Short-term Debt [Line Items]
Line of credit principal amount	$ 1,000
Credit facility interest rate	11.00%
Increase in credit facility rate	16.00%
Credit facility maturity date	Jul. 31, 2020
2010 to 2018 [Member]
Short-term Debt [Line Items]
Aggregate principal amount		2,175
Proceeds from unrelated third party		50
Total principal amount		$ 2,225
Debt instrument interest rate		11.00%
Debt instrument maturity date		Jul. 31, 2020

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019	Feb. 28, 2019
Subsidiary, Sale of Stock [Line Items]
Common stock share outstanding	154,810,655		154,810,655
Common stock shares issued	154,810,655		154,810,655
Dividends, preferred stock
Number of common stock issued during period
Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference, per share value	$ 100
Dividends payable amount per share	10
Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference, per share value	1
Dividends payable amount per share	0.10
Preferred stock, redemption price per share	$ 0.10
Convertible preferred stock, shares issued upon conversion	25
Preferred stock conversion premium price per share	$ 4.20
Preferred stock, conversion basis	Each share of Series C Preferred Stock is convertible into 25 shares of the Company's common stock upon payment of a conversion premium of $4.20 per share of common stock.
Stock redemption, shares	62,048
Stock redemption, amount	$ 25
Share price per share	$ 0.40
Preferred stock, redemption price	$ 15
Accrued expenses	$ 10
Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference, per share value	$ 1,500
Convertible preferred stock, shares issued upon conversion	5,000
Preferred stock, conversion basis	Each share of Series D Preferred Stock is convertible into 5,000 shares of the Company's common stock.
Stock redemption, shares
Stock redemption, amount
Common stock share outstanding				2,782
Common stock shares issued				13,910,000

Basic and Diluted Loss Per Sh_3

Basic and Diluted Loss Per Share - Schedule of Common Shares Not Included in Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Class of Stock [Line Items]
Total		15,461,200
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Total		1,551,200
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Total		13,910,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Dr. Phillip Frost [Member] - USD ($)	Jan. 02, 2008	Feb. 29, 2016	Oct. 31, 2019	Oct. 31, 2018
Lease term	5 years
Lease expired date	Dec. 31, 2012
Rental payments	$ 1,250		$ 0	$ 76,000
Reduced amount in rental payments		$ 0
Rent expense
Maximum [Member]
Beneficial ownership percentage	10.00%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) $ in Thousands	May 03, 2019USD ($)	Sep. 30, 2007USD ($)	Oct. 31, 2019USD ($)ft²
Lease expiration, date			2012
Area of land | ft²			4,000
Operating lease, description			The lease commenced September 15, 2014 and originally expired on September 30, 2015 and we exercised our option to renew the lease and extended the expiration to September 15, 2017.
Accrued unpaid rent forgiveness, inventory exchanged value	$ 15
Inventory written off value in gain on forgiveness	$ 15
Sing Lin Technologies [Member]
Payables due to related party			$ 41
Total cost		$ 471
Agreement Transition Description		The Agreement provided for the Company to purchase approximately $2.6 million of Exer-Rest units within one year of the September 2008 acceptance of the final product. The Agreement further provided for the Company to purchase $4.1 million and $8.8 million of Exer-Rest products in the second and third years following such acceptance, respectively.
Payments from company			1,700
Minimum future purchase			$ 13,900
Sing Lin Technologies [Member] | One Year [Member]
Purchase of Exer-Rest units		$ 2,600
Sing Lin Technologies [Member] | Second Year [Member]
Purchase of Exer-Rest units		4,100
Sing Lin Technologies [Member] | Three Year [Member]
Purchase of Exer-Rest units		8,800
Sing Lin Technologies [Member] | Tooling Cost [Member]
Consideration		150
Sing Lin Technologies [Member] | Concepts and Designs [Member]
Consideration		$ 150